Equity Profile

ABT

Abbott Laboratories

Health CareHealth Care Equipment$192.5B

Jul16Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Abbott Laboratories (ABT) is a global health care company that develops and manufactures a wide range of medical devices, diagnostics, and nutritional products. With a market cap of $193 billion, Abbott plays a crucial role in the health care sector, particularly in areas like diabetes care and cardiovascular health.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$1.28

Revenue

Revenue figures provide insight into the company's overall sales performance and market demand for its products.

$12.5B

Wall Street expectations, options signals, track record, and call prep available with Pro.

ABT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+1.05%

Avg Stock Reaction

-3.34%

Last Quarter Recap

In Q1 2026, Abbott reported an EPS of $1.15, slightly beating expectations. However, the stock fell 6% the following day, indicating market concerns despite the positive earnings surprise.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Abbott to report steady earnings this quarter, with a consensus EPS of $1.28 and revenue of $12.5 billion. Investors will be watching closely for any signs of growth or challenges in the health care market.

Bull Case

If Abbott exceeds EPS and revenue expectations, it could signal strong demand for its products, potentially leading to a positive market reaction and renewed investor confidence.

Bear Case

Conversely, if Abbott fails to meet expectations or provides weak guidance, it could raise concerns about its growth prospects, leading to a decline in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.28

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$12.5B

Revenue figures provide insight into the company's overall sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Abbott's EPS exceed the consensus estimate of $1.28?

A beat on EPS could indicate stronger-than-expected demand for Abbott's products and boost investor confidence.

What guidance will Abbott provide for future revenue growth?

Future revenue guidance will be crucial for assessing Abbott's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Abbott's ability to drive revenue growth in emerging markets, particularly in diabetes care.

Supporting Evidence

Abbott's recent product launches have shown strong initial demand, which may not be fully reflected in analyst estimates.

The company's historical performance indicates a consistent ability to exceed EPS expectations, suggesting potential upside.

Key Risk

If Abbott's revenue growth in emerging markets significantly outpaces expectations, it could challenge the current consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Abbott's ability to maintain growth in a competitive health care landscape, making these metrics critical.

Bull Confirmed If

An EPS of $1.30 or higher, coupled with revenue exceeding $12.7 billion, would confirm the bull case.

Bear Confirmed If

An EPS below $1.26 and revenue below $12.3 billion would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±8.67%

Historical Avg

±4.6%

Pricing rich

The options market is pricing in a significant potential move in either direction, suggesting that investors expect volatility around the earnings report.

Options are pricing ±8.7% while ABT has averaged ±4.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

26.1%

Calls (760K)P/C Ratio: 0.51Puts (2.8M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Abbott beats expectations, history suggests the stock could rise by an average of 2.89% on the first day.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may experience muted movement.

Miss

Should Abbott miss expectations, history indicates the stock could drop by an average of 3.34% on the first day.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

R-GARichard Dean Dr McCormickRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their market reception.
2Details on revenue growth in emerging markets.
3Management's outlook on competitive pressures in the health care sector.
4Insights into supply chain stability and its impact on production.
5Any changes in guidance for future quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Fastenal Company

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$1.28

Revenue

Revenue figures provide insight into the company's overall sales performance and market demand for its products.

$12.5B

Wall Street expectations, options signals, track record, and call prep available with Pro.

ABT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+1.05%

Avg Stock Reaction

-3.34%

Last Quarter Recap

In Q1 2026, Abbott reported an EPS of $1.15, slightly beating expectations. However, the stock fell 6% the following day, indicating market concerns despite the positive earnings surprise.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Abbott exceeds EPS and revenue expectations, it could signal strong demand for its products, potentially leading to a positive market reaction and renewed investor confidence.

Bear Case

Conversely, if Abbott fails to meet expectations or provides weak guidance, it could raise concerns about its growth prospects, leading to a decline in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.28

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$12.5B

Revenue figures provide insight into the company's overall sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Abbott's EPS exceed the consensus estimate of $1.28?

A beat on EPS could indicate stronger-than-expected demand for Abbott's products and boost investor confidence.

What guidance will Abbott provide for future revenue growth?

Future revenue guidance will be crucial for assessing Abbott's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Abbott's ability to drive revenue growth in emerging markets, particularly in diabetes care.

Supporting Evidence

Abbott's recent product launches have shown strong initial demand, which may not be fully reflected in analyst estimates.

The company's historical performance indicates a consistent ability to exceed EPS expectations, suggesting potential upside.

Key Risk

If Abbott's revenue growth in emerging markets significantly outpaces expectations, it could challenge the current consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Abbott's ability to maintain growth in a competitive health care landscape, making these metrics critical.

Bull Confirmed If

An EPS of $1.30 or higher, coupled with revenue exceeding $12.7 billion, would confirm the bull case.

Bear Confirmed If

An EPS below $1.26 and revenue below $12.3 billion would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±8.67%

Historical Avg

±4.6%

Pricing rich

The options market is pricing in a significant potential move in either direction, suggesting that investors expect volatility around the earnings report.

Options are pricing ±8.7% while ABT has averaged ±4.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

26.1%

Calls (760K)P/C Ratio: 0.51Puts (2.8M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Abbott beats expectations, history suggests the stock could rise by an average of 2.89% on the first day.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may experience muted movement.

Miss

Should Abbott miss expectations, history indicates the stock could drop by an average of 3.34% on the first day.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

R-GARichard Dean Dr McCormickRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their market reception.
2Details on revenue growth in emerging markets.
3Management's outlook on competitive pressures in the health care sector.
4Insights into supply chain stability and its impact on production.
5Any changes in guidance for future quarters.